Kevin B Porter

US Patent:

8241638, Aug 14, 2012

Filed:

Nov 2, 2007

Appl. No.:

11/982488

Inventors:

Monika Simmons - Germantown MD, US
Kevin R. Porter - Boyds MD, US

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

A61K 39/12

US Classification:

4242181

Abstract:

The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.

US Patent:

8440202, May 14, 2013

Filed:

Oct 26, 2011

Appl. No.:

13/281473

Inventors:

Monika Simmons - Germantown MD, US
Kevin R. Porter - Boyds MD, US
Wellington Sun - Guaynabo PR, US

Assignee:

The United States of America as Represented by the Secretary of the Navy - Washington DC

International Classification:

A61K 39/12
A61K 48/00

US Classification:

4242181, 4241921, 514 44 R

Abstract:

The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.

US Patent:

20070134694, Jun 14, 2007

Filed:

Oct 26, 2006

Appl. No.:

11/586894

Inventors:

Timothy Burgess - Silver Spring MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Nicole Martin - Olney MD, US
Mary Marovich - Bethesda MD, US

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

The invention concerns a method of detecting dengue infection by detecting anti-dengue neutralizing substances including anti-dengue antibody by measuring inhibition of dengue binding to dentritic cell-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (DC-SIGN) or liver/lymph node-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (L-SIGN). DC-SIGN or L-SIGN can be used expressed in transfected cell lines that normally are not infected by dengue virus. The invention also concerns a method of detecting anti-dengue drugs by their ability to inhibit binding of dengue virus to DC-SIGN or L-SIGN.

US Patent:

20070134695, Jun 14, 2007

Filed:

Oct 26, 2006

Appl. No.:

11/586895

Inventors:

Timothy Burgess - Silver Spring MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Mary Marovich - Bethesda MD, US

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

The invention concerns a method for diagnosing dengue invention early after dengue virus infection. The method comprises binding dengue virus contained in sera from infected patients with dentritic cell-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (DC-SIGN) or liver/lymph node-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (L-SIGN). DC-SIGN or L-SIGN can be expressed in transfected B cells or adhered to other surfaces. Measurement of binding is by immunocytometry, microscopy or other antibody based methods.

US Patent:

20080219930, Sep 11, 2008

Filed:

Aug 21, 2006

Appl. No.:

11/507322

Inventors:

Timothy H. Burgess - Silver Spring MD, US
Kevin R. Porter - Boyds MD, US
Daniel A. Freilich - Washington DC, US
Denise L. Doolan - Camp Hill, AU

International Classification:

A61K 49/00

US Classification:

424 92

Abstract:

The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive method include Yorkshire or Lancashire as well as miniature pig breeds.

US Patent:

58956514, Apr 20, 1999

Filed:

Jun 27, 1996

Appl. No.:

8/671056

Inventors:

Monika Simmons - Gaithersburg MD
Curtis G. Hayes - Frederick MD
Kevin R. Porter - Gaithersburg MD

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

A61K 3900
A61K 3912

US Classification:

4241921

Abstract:

A recombinant fusion protein (DEN-2 MBP) containing the B domain of the due (DEN 2 envelope protein is disclosed as a candidate subunit immunogen for vaccination against dengue virus infection. A gene fragment encoding amino acid 298 to amino acid 400 of the DEN-2 virus envelope was expressed as a fusion protein with the maltose binding protein (MBP) of Escherichia coli (E. coli). The recombinant fusion protein was purified and analyzed for its antigenicity imunogenicity and ability to protect mice against lethal challenge. This antigen is detected by monoclonal antibody (3H5) which is specific for a neutralizing epitope on the DEN-2 envelope and reacted with homologous polyclonal mouse immune ascitic fluid and DEN-2 immune human sera. A recombinant fusion plasmid bearing the DEN-2 MBP DNA sequence, expressing the fusion product in E. coli is disclosed.

US Patent:

20140271714, Sep 18, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/835993

Inventors:

Monika Simmons - Germantown MD, US
Kevin R. Porter - Boyds MD, US
Kanakatte Raviprakash - Clarksville MD, US
Wellington Sun - Kensington MD, US

International Classification:

A61K 39/12

US Classification:

4242181

Abstract:

The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.